NurExone Biologic Inc.

TSXV:NRX Stock Report

Market Cap: CA$59.0m

NurExone Biologic Valuation

Is NRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NRX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NRX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NRX?

Key metric: As NRX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for NRX. This is calculated by dividing NRX's market cap by their current book value.
What is NRX's PB Ratio?
PB Ratio15.6x
BookUS$2.58m
Market CapUS$42.21m

Price to Book Ratio vs Peers

How does NRX's PB Ratio compare to its peers?

The above table shows the PB ratio for NRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.1x
VEXT Vext Science
0.4x111.1%CA$45.8m
MDP Medexus Pharmaceuticals
1.2x49.9%CA$52.0m
DMT Small Pharma
6.3xn/aCA$50.4m
XLY Auxly Cannabis Group
0.4xn/aCA$51.4m
NRX NurExone Biologic
15.6xn/aCA$59.0m

Price-To-Book vs Peers: NRX is expensive based on its Price-To-Book Ratio (15.6x) compared to the peer average (0.7x).

Price to Book Ratio vs Industry

How does NRX's PB Ratio compare vs other companies in the CA Pharmaceuticals Industry?

9 CompaniesPrice / BookEstimated GrowthMarket Cap
AVNT Avant Brands
0.1xn/aUS$4.93m
BZAM BZAM
0.08xn/aUS$4.88m
CPTR Captor Capital
0.07xn/aUS$1.99m
IDVR INDVR Brands
0.1xn/aUS$1.17m
NRX 15.6xIndustry Avg. 1.1xNo. of Companies12PB00.61.21.82.43+
9 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: NRX is expensive based on its Price-To-Book Ratio (15.6x) compared to the Canadian Pharmaceuticals industry average (1x).

Price to Book Ratio vs Fair Ratio

What is NRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NRX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio15.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NRX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Fennec Pharmaceuticals

US$117.3m

Operates as a biopharmaceutical company in the United States.

FRX

US$6.50

7D

7.6%

1Y

-44.2%

Medexus Pharmaceuticals

CA$52.0m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.15

7D

5.4%

1Y

40.5%

Verano Holdings

CA$850.9m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.32

7D

-12.8%

1Y

-60.6%